Business
Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the fourth dosage cohort in the ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center ("Moffitt") under the direction of Dr. Robert Wenham,
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"Fourth cohort dose is three million CAR positive cells; thirty times higher than the first cohort dose","length":102,"tagName":"p","attribs":{}},{"type":"text","content":"SAN JOSE, Calif., June 23, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the fourth dosage cohort in the ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center ("Moffitt") under the direction of Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt, the principal investigator.","length":665,"tagName":"p"},{"type":"image","alt":"Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)","displaySize":"","headline":null,"caption":"Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":119,"url":"https://media.zenfs.com/en/prnewswire.com/3ba55e340de170a9f97c46887c8c8549"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4B69KZz1nJO8NbFw7Kh3Pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3ba55e340de170a9f97c46887c8c8549","width":400,"height":119}},"href":"https://mma.prnewswire.com/media/602982/ITUS_Corporation_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The fourth cohort in the trial will receive a dose of three million CAR-positive cells per kilogram of body weight, representing a thirtyfold increase from the first cohort. No dose-limiting toxicities were observed in the third cohort, enabling advancing to the fourth dosage cohort. This planned escalation marks a key step in assessing the safety and therapeutic effect of CAR-T cell therapy in patients with ovarian cancer.","length":427,"tagName":"p"},{"type":"text","content":"Anixa's FSHR-mediated CAR-T technology targets the follicle-stimulating hormone receptor (FSHR), which research indicates is exclusively expressed on ovarian cells, tumor vasculature, and certain cancer cells. The first-in-human trial (NCT05316129) is enrolling adult wo...